Novo Nordisk Discloses Insider Share Transactions
Ticker: NONOF · Form: 6-K · Filed: Aug 8, 2025 · CIK: 353278
Sentiment: neutral
Topics: insider-trading, disclosure, regulation
Related Tickers: NVO
TL;DR
Novo Nordisk execs and board members bought/sold shares on Aug 7, 2025, per market abuse rules.
AI Summary
On August 7, 2025, Novo Nordisk A/S disclosed transactions in its own shares by board members, executives, and associated persons. This disclosure is in accordance with Article 19 of Regulation No. 596/2014 on market abuse, which governs trading by insiders.
Why It Matters
This filing provides transparency into the trading activities of Novo Nordisk's leadership, offering insights into their confidence in the company's performance.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of insider trading activity and does not indicate any new material risks for the company.
Key Players & Entities
- Novo Nordisk A/S (company) — Registrant
- August 7, 2025 (date) — Date of transactions
- Regulation No. 596/2014 (regulation) — Governing market abuse
- Article 19 (regulation) — Specific article on insider trading disclosure
FAQ
What type of transactions are being disclosed by Novo Nordisk?
The filing discloses transactions in Novo Nordisk shares made by the company's board members, executives, and their associated persons.
What regulation governs these disclosures?
These disclosures are made in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
When were these transactions made?
The transactions disclosed in this filing occurred on or before August 7, 2025.
What is the purpose of this type of filing?
The purpose is to provide transparency regarding trading activities by individuals with inside information about the company.
Is this filing related to annual financial reports?
No, this is a Form 6-K, which is a report of foreign private issuers, and is distinct from the annual report filed on Form 20-F.
Filing Stats: 672 words · 3 min read · ~2 pages · Grade level 14.3 · Accepted 2025-08-08 09:34:03
Filing Documents
- f6k_080725.htm (6-K) — 34KB
- logo.jpg (GRAPHIC) — 76KB
- ca.jpg (GRAPHIC) — 24KB
- 0001171843-25-005208.txt ( ) — 174KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized. Date: August 7, 2025 NOVO NORDISK A/S Maziar Mike Doustdar Chief Executive Officer